Xspray Pharma AB
xspraypharma.com
Actively hiring
Prescription Drugs
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Unique technology, Unique market. Xspray Pharma’s unique technology could improve the quality of life, and make it possible for more patients to access improved Protein Kinase Inhibitor (PKI) drugs for treatment of cancer.
News
Report
Report
XSpray Pharma AB: Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA,
Read more
Report
XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA,
Read more
Report
Xspray Pharma's XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose
Xspray Pharma AB, a biotechnology company focused on developing improved protein kinase inhibitors for cancer treatment using its proprietary HyNap technology, announced today new clinical data from its XS003 registration study program. XS003 is an amorph
Read more
Report
Xspray Pharma's XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA at Reduced Dosage
Read more
Report
Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)
--Xspray Pharma AB, has signed an agreement with EVERSANA to support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia and acute lymphatic leukemia. "As we explored
Read more
Report